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SUMMARY
Nanoparticles (NPs) have the potential to revolutionize drug delivery, however, administering
them to the human body without the need for intravenous injection remains a major challenge. In
this study, a series of near-infrared (NIR) fluorescent NPs were systematically varied in chemical
composition, shape, size, and surface charge, and their biodistribution and elimination were
quantified in rat models after lung instillation. We demonstrate that NPs with hydrodynamic
diameter (HD) less than ≈ 34 nm and a non-cationic surface charge translocate rapidly from lung
to mediastinal lymph nodes. NPs of HD < 6 nm can traffic rapidly from the lungs to lymph nodes
and the bloodstream, and then be subsequently cleared by the kidneys. We discuss the importance
of these findings to drug delivery, air pollution, and carcinogenesis.
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Nanoparticles (NPs) have been proposed as diagnostic, therapeutic, and theragnostic agents
for a wide variety of human diseases.1-3 Lung-based drug delivery of NPs is receiving
increased attention due to the large surface area available and the minimal anatomical
barriers limiting access to the body.4 In this study, we explore whether it would be possible
to administer NPs via the lung, and in so doing, attempt to define the key parameters that
mediate lung to body NP translocation and subsequent elimination (i.e., clearance).
Lung-administered NPs also have significant implications for air pollution. Recent
toxicological studies have confirmed that nano-sized or ultrafine particles reach deep into
the alveolar region of the lungs5,6 and cause severe inflammation reactions due to their large
surface areas per mass.6 Inhalation of NPs is increasingly recognized as a major cause of
adverse health effects, and has especially strong influence on the cardiovascular system and
hemostasis, leading to increased cardiovascular morbidity and mortality.6-8
The standard approach for studying the translocation of inhaled NPs and ultrafine air
pollutants from the lungs to extrapulmonary compartments in animals is to perform post-
mortem analysis of tissues after inhalation of carbon-based particles,9 radiotracers,10 or
neutron-activated metal particles.11-13 Recently, Moller et al. reported that ultrafine NPs
could pass from the lungs into bloodstream and extrapulmonary organs in humans.10
Pulmonary macrophages clearly play a key role in the removal of particles from the alveolar
gas exchange surface. Harmsen et al. elegantly demonstrated alveolar macrophage-mediated
translocation of micrometer-sized particles from the lung surface to the regional
tracheobronchial lymph nodes (LNs).14 However, this macrophage-mediated process takes a
relatively long time, from several hours to weeks.13-15
In this study, we are interested in much more rapid translocation of NPs (on the order of
minutes) from the lungs to the draining LNs, to the bloodstream, and to the rest of body. We
systematically varied the chemical composition, size, shape, and surface charge of near-
infrared (NIR) fluorescent NPs in order to determine how their physicochemical properties
affect trafficking across the alveolar surface barrier into tissue, and once in the tissue, their
fate with respect to biodistribution and clearance. Enabling this study is our intraoperative
FLARE™ (Fluorescence-Assisted Resection and Exploration) imaging system, which
permits two independent channels (700 nm and 800 nm) of NIR fluorescence images to be
acquired simultaneously with color video images.16,17 NIR fluorescence imaging provides
several advantages for quantifying the process of NP trafficking including a low
autofluorescence background, real-time imaging, real-time overlay with anatomy, and
highly sensitive detection of targets several millimeters deep in tissue.18
As shown in Table 1, two distinct families of NPs were engineered with varying chemical
composition, shape, size, and surface charge (see also Fig. 1a). Inorganic/organic hybrid
nanoparticles (INPs) emitted at 800 nm. Quantum dots (QDs) with various core(shell) and
organic coating ligands were used to produce a variety of sized and charged INPs (INP1 -
INP5). Gel filtration chromatography (GFC) was used to measure the final hydrodynamic
diameter (HD), which ranged from 5 to 23 nm in phosphate-buffered saline (PBS)
(Supplementary Fig. 2 online). It is important to note that the surface-charged INPs with
either carboxylic (INP3 and INP5) or amino (INP4) groups showed high protein adsorption,
which contributed to a significant increase in final HD when exposed to 100% serum.19 To
study the effect of surface charge in detail, INP1 and INP2 were engineered to have
zwitterionic and polar coatings, respectively, which eliminated serum protein binding and
resulted in a constant HD in PBS and serum.19,20 To engineer INPs over 50 nm in HD, we
used silica nanospheres doped with QDs and conjugated NIR fluorophore CW800 on the
silica surface (INP6 - INP9). These silica NPs did not associate with serum proteins, thus the
original size was maintained after 1 h serum incubation at 37°C. Organic nanoparticles
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(ONPs) were designed to emit 700 nm NIR fluorescence, which permitted comparison of the
effect of NP chemical composition with 800 nm emitting INPs.
To investigate the role of HD in the translocation of NPs from the lung to extrapulmonary
compartments of the body, we systematically increased the size of fluorescent NPs from 5 to
300 nm. As shown in Figure 1b, translocation of INP5 and larger particles was severely
restricted over 30 min post-administration, which indicates that the size threshold for rapid
translocation of NPs from lungs to LNs corresponds to an HD of < 38 nm in serum.
Interestingly, a similar size threshold was found in the ONPs; i.e., between 34 nm (ONP3)
and 48 nm (ONP4) in HD, suggesting that the rapid translocation from lungs to mediastinal
LNs is primarily governed by the size of NPs, irrespective of chemical composition, shape,
and conformational flexibility. For charged NPs, non-specific adsorption of endogenous
proteins, mostly albumins, can result in a large increase in final HD by 10 to 50 nm (see
Supplementary Fig. 2a online).19,21
Below the size threshold of 34 nm, the surface charge of NPs also plays a critical role for
rapid translocation from lungs to regional LNs (Fig. 1c). To investigate this effect in detail,
zwitterionic (INP1 and ONP1), polar (INP2 and ONP2), anionic (INP3 and ONP3), and
cationic (INP4) coatings were introduced to both INPs and ONPs, and the charge effect was
compared. First, hydrophilic and neutral organic coatings such as zwitterionic cysteine and
polar PEG ligands prevented adsorption of serum proteins19 and led to rapid translocation of
NPs into the mediastinal LNs. Nemmar et al. demonstrated the importance of surface
properties of NPs in hemostasis inducing effects, such as platelet activation, which may lead
to thrombosis.9 On the other hand, the behavior of highly net charged NPs (charge-to-
volume ratio > ±1) was more complicated. Since both anionic and cationic charged
molecules quickly adsorb endogenous proteins in the lungs, similar migration results were
expected among the batches.19,21 The translocation behavior of NPs in the alveolar lining
fluid was, however, very different. Carboxylic group-modified INP3 was found in the LNs
within 30 min post-administration, while no significant translocation was observed for the
cationic INP4 (Fig. 1c, bottom), even though they were engineered from the same batch of
CdTe(CdSe) nanocrystals. Since it is well known that cationic charged materials can be
taken up by cells,22 sometimes causing acute cytotoxicity, it is likely that cationic particles
(INP4) were rapidly taken up by pulmonary macrophage and/or epithelial cells shortly after
administration, making them unavailable for translocation to LNs. As cationic NPs remain
in pulmonary cells for a long time, they may cause severe lung injury.23 Our results are also
consistent with recent reports on pulmonary drug delivery systems that suggest surface
charge is a key factor affecting translocation efficiency.24
The majority of the administered NPs in our study remained in the lungs, with small
amounts rapidly appearing in the mediastinal LNs within 30 min post-administration. Even
more rapid translocation (in minutes) from the site of deposition to LNs was only observed
in smaller INPs. In particular, for the smallest NPs (INP1, 5 nm), migration to the
mediastinal LNs was very fast (within 3 min), and there was measurable NP accumulation in
the kidneys and excretion into urine at 30 min post-administration (Fig. 2a). On the other
hand, INP3 (27 nm) showed slower accumulation into LNs (<10 min) and blood (<20 min).
As shown in Figure 2b, most of our ultra-small NPs were found in the kidneys, with the
smallest ones also found in the urine (Supplementary Fig. 4). Because of the zwitterionic
surface coating and small HD,19,25 there were virtually no NPs trapped in the hepatic
clearance route, such as liver, bile, and intestine (Fig. 2b).
To confirm the qualitative observations made using NIR fluorescence, INPs were labeled
with 99mTc-MAS3 (MAS3 is S-acetylmercaptoacetyltriserine) and experiments repeated to
better quantitate NP translocation from the lung airspaces to LN, blood, and eventually
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urine. Blood clearance was measured by intermittent sampling of the tail vein. The small
molecule sodium pertechnetate (TcO4−) was used as a control and showed rapid uptake into
blood, consistent with direct translocation through the alveolar air-blood barrier,10 excretion
into urine, and moderate uptake in LNs at 1 h post-instillation (Fig. 2c and Supplementary
Fig. 5). On the other hand, INP1 and INP3 appeared in the blood after a short lag, and at
concentrations inversely proportional to HD. Since LN uptake of NPs was more pronounced
than TcO4−, this suggests that there could be another pathway for translocation of NPs from
lung airspaces into blood, one involving transient passage through LNs. Our findings are
also consistent with the literature showing that large cationic liposomes provide an improved
therapeutic window to treat lung epithelium. Interestingly, almost no translocation of INP4
was seen in the LNs or carcass (Fig. 2c and Supplementary Fig. 4).
In this study, we have systematically engineered various NPs to demonstrate the effect of
particle characteristics on their ability to translocate from the lungs into the LNs and
bloodstream, and on their fate in vivo. Although NPs are stable and show a narrow size
distribution in PBS, this study suggests that the final HD as measured in serum, along with
surface charge, play critical roles in determining the ultimate migration, biodistribution, and
clearance of NPs deposited in the lungs. The key findings of our study are: 1) a size
threshold of ≈ 34 nm mediates whether there is rapid trans-epithelial translocation of NPs
from the alveolar luminal surface into the septal interstitium, followed by quick
translocation to the regional draining LNs where further translocation into the bloodstream
could occur, 2) below this size threshold of ≈ 34 nm, surface charge is a major factor that
mediates translocation, with zwitterionic, anionic, and polar surfaces being permissive, but
cationic surfaces being restrictive, and 3) when HD is less than 6 nm and surface charge is
zwitterionic, NPs can enter the bloodstream quickly from the alveolar airspaces and can
ultimately be cleared from the body via renal filtration. The latter finding represents what we
believe to be the first description of a “complete cycle” of trafficking of NPs from the
environment (i.e., lung airspaces) through the body and back to the environment (i.e., after
excretion into urine).
The implications of these findings for drug delivery, air pollution control, and
carcinogenesis are significant. Our results might prove useful to investigators trying to
engineer inhaled NP-based drugs. First, the data are consistent with the literature showing
that large (>100 nm) cationic liposomes provide an improved therapeutic window to treat
lung epithelium. That is, systemic absorption is very low, presumably because these NPs
exceed the size and charge thresholds defined above (with whatever systemic absorption
observed likely due to liposome instability). Second, and more importantly, engineering NP-
based drugs to be zwitterionic and < 6 nm in HD should result in rapid and high levels of
drug in the bloodstream after administration, while permitting renal clearance of drug not
bound to its target. And finally, non-cationic NPs ≤ 34 nm and ≥ 6 nm should provide high
levels of drug to pulmonary LNs, which could be used to delivery antibiotics and anti-
inflammatory drugs to treat lung infections, tumor metastases, and inflammatory conditions.
With respect to air pollution and carcinogenesis, our data suggest that non-cationic NPs with
a HD in serum ≤ 34 nm are potentially the most dangerous in that they rapidly traverse the
epithelial barrier, enter regional LNs, and if ≥ 6 nm are not cleared efficiently by the
kidneys. Thus, exposure of internal organs and tissues will be maximal. Chemical strategies
that alter the size and charge of pollutants to be large (> 34 nm) and cationic could
potentially minimize airspace to body translocation, and provide time for macrophage-
mediated clearance. Once in the body and lodged in LNs (i.e., 6 nm ≤ HD ≤ 34 nm), non-
cationic NPs could cause inflammation and/or contribute to carcinogenesis. Smaller NPs,
such as those ≈ 5 nm in HD, are even more concerning for carcinogenesis and distal
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inflammation because they are capable of traveling from the lung to the bloodstream, and
once in the bloodstream, can potentially reach every tissue and organ in the body.26
MATERIALS AND METHODS
Synthesis of inorganic/organic nanoparticles (INPs)
CdSe(ZnCdS) nanocrystals were used to produce INP1 and INP2 with cysteine and
dihydrolipoic acid (DHLA)-conjugated polyethylene glycol spacer (DHLA-PEG, MW 1
kDa) coating, respectively, via modification of previously reported procedures (see
Supplementary Information online).19,25 800 nm NIR emitting fluorophore CW800 (LI-
COR, Lincoln, NE) was conjugated on the QD surface in PBS, pH 7.8 (labeling ratio ≈1.4).
CdTe(ZnS) core(shell) NIR QDs were purchased from Invitrogen (QDot 800 ITK, Carlsbad,
CA) with carboxylated PEG (INP3) or amino PEG (INP4) ligand coating.27 To engineer
INP5, α-amino-ω-carboxylate PEG 3.4 kDa (Nektar, San Carlos, CA) was conjugated
through conventional EDC chemistry. INP6 to INP9 silica NPs were prepared by
incorporating CdSe(ZnS) QDs in the silica shells, and conjugating CW800 fluorophores on
the surface of nanospheres to engineer larger sizes of NPs (see Supplementary Information
online).28
Synthesis of organic nanoparticles (ONPs)
ONP1 was prepared by a reaction of Cy5.5-NHS (Amersham Biosciences, Piscataway, NJ)
with human serum albumin (HSA; American Red Cross, Washington, DC) in PBS at pH
7.8, followed by purification by gel filtration chromatography (GFC) using an Econo-Pac P6
cartridge (Bio-Rad, Hercules, CA). The labeling ratio was 2.6, estimated using the extinction
coefficients of HSA (ε280nm = 32,900 M−1cm−1) and Cy5.5 (ε675nm = 19,000 M−1cm−1).
ONP2 was obtained by simply mixing two equiv of Cy5.5-NHS with amino mPEG 20 kDa
(Nektar, San Carlos, CA) in PBS at pH 7.8, followed by GFC purification (labeling ratio =
1). A size series of nanospheres based on polystyrene and polyacrylate block copolymers
(ONP3 - ONP7) were purchased from Phosphorex, Inc. (Fall River, MA) and conjugated
covalently to Cy5.5 (5 to 10 fluorophores per mole of polyacrylate) to produce 700 nm NIR
fluorescence emission (see Supplementary Information online).
Double-lumen balloon catheter for NP administration into lungs
Administration of NPs into the lung without backflow entering the trachea and obscuring
mediastinal LNs imaging was a major challenge. To solve this problem, we developed a
custom-built double-lumen balloon catheter that blocked mucociliary flow into the trachea
while animals were being ventilated (see Supplementary Fig. 3 online). A custom-made 20
cm double-lumen balloon catheter was developed by Pelham Plastics, Inc. (Pelham, NH)
with the following specifications: OD = 1.5 mm; a thru lumen = 0.71 mm for ventilation; a
balloon lumen = 0.5 mm; inflation balloon OD = 2.5 mm. The catheter was inserted through
a trachea cannula (OD = 2.1 mm, ID = 1.8 mm) into the right mainstem bronchus and the
outer balloon was inflated. The inflated balloon remained in position for 1 h to block
backflow of deposited NPs. The thru lumen was used for administration of NP solutions
deep into the lung followed by a puff of air during an inspiration phase to ensure delivery of
a NP bolus deep into the lung. Both side lungs were ventilated for 60 min.
Animal models
All animals were used under the supervision of an approved institutional protocol. 500 to
550 g Sprague-Dawley (SD) male rats from Charles River Laboratories (Wilmington, MA)
were anesthetized with 65 mg/kg intraperitoneal pentobarbital, and were mechanically
ventilated by tracheostomy using an MRI-1 ventilator (CWE, Inc. Ardmore, PA) at 80
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breaths per min using room air. A specially designed double-lumen balloon catheter was
placed in the right mainstem bronchus as described above, and a minimal volume (50 - 100
μL) of NP solution (a mixture of 800 nm INPs and/or 700 nm ONPs) in PBS was then
administered through the thru lumen into lungs at a dose of 10 pmol/g of animal weight.
After each study, animals were euthanized by intraperitoneal injection of 200 mg/kg
pentobarbital, a method consistent with the recommendations of the Panel on Euthanasia of
the American Veterinary Medical Association.
Real-time intraoperative NIR fluorescence imaging
The dual-channel intraoperative NIR fluorescence imaging system (FLARE™;
Fluorescence-Assisted Resection and Exploration) optimized for animal surgery has been
described in detail previously.16,17 Excitation fluence rate for white light, 700 nm NIR
excitation light, and 800 nm NIR excitation light were 20,000 lux, 3.5 mW/cm2, and 10
mW/cm2, respectively. The translocation of NPs into LNs and bladder was measured using
the following method: the fluorescence (Fl) and background (BG) intensity of a region of
interest over each organ was quantified using custom FLARE™ software at the following
time points - 0, 1, 2, 5, 10, 20, 30, 40, 50, and 60 min. Signal-to-background ratio (SBR),
defined as SBR = (Fl – BG)/BG was then plotted as a function of time. For measuring NP
concentration in blood, approximately 20 μL of blood was collected from the tail vein using
glass capillary tubes, and the SBR was measured over time. At least three animals were
analyzed at each time point. Statistical analysis was carried out using the unpaired Student’s
t-test or one-way analysis of variance (ANOVA). Results were presented as mean ± S.D.
and curve fitting was performed using Prism version 4.0a software (GraphPad, San Diego,
CA).
99mTc-labeling of NPs and radioscintigraphic imaging
99mTc-conjugated NPs were prepared using high-specific-activity N-hydroxysuccinimide
(NHS) ester of 99mTc-MAS3 as described previously.19,20,26 50 - 100 μL of 99mTc-
conjugated NPs (100 - 300 μCi) were administered intratracheally into SD rats. Sodium
pertechnetate (TcO4−) was used as a control. Measurement of blood clearance was
performed by intermittent sampling of the tail vein. Rats were sacrificed at 1 h post-
administration. To measure total urinary excretion, the bladder was removed en masse and
combined with excreted urine prior to measurement of radioactivity in a dose calibrator. The
radioactivity of each resected major organ was measured on a Wallac Wizard (model 1470,
Perkin Elmer, Wellesley, MA) 10-detector gamma counter. Gamma radioscintigraphy was
performed with a Research Digital Camera (Isocam Technologies, Castana, IA) equipped
with a 1/2″ NaI crystal, 86 photomultiplier tubes, and high-resolution (1 mm) lead
collimator.
Histological analysis of tissues
Tissues were resected 1 h post-administration, fixed in 10% formalin for 3 h, molded with
Tissue-Tek OCT compound (Fisher Scientific, Pittsburgh, PA), and frozen in liquid
nitrogen. Frozen sections were cut to a 10 μm thickness and stained with hematoxylin and
eosin (Histotec Laboratories). Lung, liver, spleen, kidney, pancreas, intestine, muscle, and
LNs were examined by a 4-channel fluorescence microscope. The excitation and emission
filters used were 650 ± 22 nm and 710 ± 25 nm for NIR #1, and 760 ± 20 nm and 790 nm
longpass for NIR #2, respectively.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
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Figure 2.
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